Affimed announced that the French National Agency for the Safety of Medicines and Health Products has authorized a Clinical Trial Application for the phase 1 study of AFM28 in relapsed/refractory acute myeloid leukemia, or AML. CTA applications for AFM28-101 in other European jurisdictions are ongoing, and additional applications are planned for submission early in 2023. Additionally, Affimed plans to investigate AFM28 in combination with allogenic natural killer cell therapy.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AFMD:
- Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia
- Affimed Plunges after Detailing New Plans
- Affimed price target lowered to $8 from $12 at Truist
- Affimed presents updated data from AFM28
- Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting
